This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Citicoline (CDP-Choline)
Endogenous brain compound, dual-substrate cholinergic donor + Kennedy-pathway nucleotide — supplies both choline (for acetylcholine) and…
Aliases (9)
Overview
What is Citicoline (CDP-Choline)?
Citicoline (CDP-choline, cytidine-5'-diphosphocholine) is an endogenous intermediate in phosphatidylcholine synthesis. As a supplement (Cognizin is the patented form), it is used as a nootropic and is approved as a prescription drug for stroke and cognitive impairment in many countries (not the US).
Key Benefits
Boosts acetylcholine synthesis for memory and focus, supports membrane phospholipid synthesis, shows benefit in stroke recovery and vascular cognitive impairment, and modestly supports attention in healthy adults (Cognizin RCTs).
Mechanism of Action
Hydrolyzed in the gut to cytidine and choline, which cross the BBB and are reassembled to CDP-choline in the brain — supplying both choline (for acetylcholine) and the phospholipid-precursor pool (for membrane PC and PE). Also modulates dopaminergic tone.
Pharmacokinetics
▸Brand options8 known
StatusOTC dietary supplement (US — DSHEA); prescription Rx in Japan, Italy (Somazina), Spain, parts of EU/Latin America/Asia for stroke recovery and vascular cognitive impairment. Not FDA-approved as a drug in US.
Research Indications
This is the citicoline-distinctive mechanism
alpha-GPC contributes choline to the Kennedy pathway but supplies no cytidine (the rate-limiting nucleotide). Citicoline is the only comm…
Peptide Interactions
✅ Already in the canonical stack plan (ALCAR 500 mg AM). ALCAR provides acetyl groups for ChAT; citicoline provides choline + cytidine. Substrate pair → maxi…
✅ Already in V4 (Carlson Super DHA Gems, 2 g DHA/day). The Wurtman synaptogenesis triad — uridine (from citicoline) + choline + DHA — is the molecular substr…
✅ Already in V4 (Swanson PS, 200 mg/day). PS is another phospholipid head-group; citicoline-derived phosphatidylcholine + supplemental PS together support me…
✅ Already in V4 (Swanson NAC, 1200 mg/day). Mechanistically orthogonal — NAC is glutathione precursor; citicoline is cholinergic substrate. Stack-safe; both …
✅ Already in V4 (Doctor's Best Mg Glycinate 400 mg + Source Naturals Magtein 3 caps). NMDA modulation + cholinergic support are complementary. Stack-safe.
✅ Standard nootropic combo. Citicoline provides cholinergic substrate; caffeine antagonizes adenosine; theanine smooths the activation. All four together is …
✅ Modafinil increases cortical activation and acetylcholine demand; citicoline supplies the substrate. Anecdotally smooths modafinil cognitive ceiling on har…
✅ Bromantane upregulates tyrosine hydroxylase + dopamine synthesis; citicoline's cholinergic complement balances the catecholaminergic tilt. V5 stack alignment.
✅ Russian peptide neurotrophic agent (BDNF/NGF upregulation) is mechanism-orthogonal. Many Russian-peptide users pair with citicoline as standard cholinergic…
✅ Anxiolytic peptide, mechanism-orthogonal. Stack-safe.
✅ Mandatory pairing. Racetams increase cholinergic demand (the precise mechanism is debated but the empirical pattern is consistent across 50+ years of clini…
⚠️ Generally compatible at PRN doses (50-100 mcg) with citicoline 500 mg. Cholinergic excess unlikely at these doses. At chronic high-dose huperzine (>200 mc…
Quality Indicators
Tested third-party COA
Reputable brands publish a Certificate of Analysis for identity, potency, and contaminant testing.
GMP-certified manufacturing
Look for cGMP / NSF / USP certifications on the label.
Proprietary blends
Avoid products that hide individual ingredient amounts inside a "proprietary blend."
No origin or sourcing info
Unbranded or no-COA capsules from anonymous sellers carry quality and adulteration risk.
What to Expect
- Week 1Baseline tolerability. Most chronic-use supplements have no acute signal.
- Week 2-4Subtle baseline shift — sleep quality, mood, recovery markers.
- Week 4-8Reach steady state. Re-assess subjective + objective markers.
- Month 3+Long-term maintenance dose if benefit confirmed; otherwise stop.
Side Effects & Safety 5
Side Effects
- 1None at standard 250-500 mg/day. Citicoline has one of the cleanest safety profiles of any cognitive-enhancing supplement.
- 2Mild GI upset (nausea, loose stool, dyspepsia) — primarily at >1000 mg/day or empty stomach. Take with food.
- 3Headache — uncommon at standard dose; more common at >1500 mg/day. Sometimes signals choline overload.
- 4Insomnia / vivid dreams with PM dosing — cholinergic-driven REM activation. Late-chronotype users (the user) keep dosing AM.
- 5Mild restlessness / dyspepsia at higher doses.
When to Stop
- Mild blood-pressure changes — typically transient, not clinically meaningful. Some users report small drops or rises; mechanism unclear.
- Allergic reactions — rare; standard supplement-allergy considerations.
- Mood changes / dysphoria at chronic high doses (>2000 mg/day) — anecdotal, similar to "cholinergic dysphoria" reported with alpha-GPC at 1200 mg/day. Not seen at typical 250-500 mg dosing.
- No analogue of the Lee 2021 Korean nationwide stroke signal. No large-cohort registry has identified an excess stroke or cardiovascular risk in citicoline users. Decades of Rx-grade use in stroke recovery (where the population already has vascular disease) without a cohort signal is informative — if there were a TMAO-mediated atherogenic effect comparable to alpha-GPC's, it would have shown up.
- TMAO production: citicoline does produce some TMAO via the same gut-microbiota choline → TMA → liver FMO3 → TMAO pathway, but per-mg of choline, citicoline contributes less choline than alpha-GPC (because citicoline is ~18% choline by weight vs alpha-GPC's 41%). At 500 mg citicoline = ~90 mg choline; at 600 mg alpha-GPC = ~250 mg choline. Citicoline's TMAO load is correspondingly smaller, and the cytidine half doesn't produce TMAO at all.
- First 1-2 weeks: GI tolerance, sleep impact (especially if dosing PM). Headache possible, usually fades.
- First 4 weeks: subjective effect emerges over this window. If null after 4 weeks and a user in this archetype is choline-replete (ramped-up egg intake), reasonable to drop or reduce.
- 6 months chronic: standard bloodwork (lipid panel, hs-CRP, CMP) — unlikely to show drift but reasonable baseline check.
References
McGlade E et al. 2012, Food and Nutrition Sciences — Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women
original Yurgelun-Todd healthy-adult attention RCT.
View StudyMcGlade E et al. 2019, Journal of Attention Disorders — The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males
adolescent attention/inhibition RCT, the most-relevant-to-archetype trial.
View StudyYurgelun-Todd D et al. 2008/2010 — Citicoline in middle-aged women, attention RCT
attention/CPT effect replication.
View StudyBruce SE et al. 2014, Psychopharmacology — Improvements in concentration, working memory and sustained attention following consumption of a natural citicoline–caffeine beverage
adolescent males, MRS-tracked anterior cingulate glutamate biomarker.
View StudyNakazaki E et al. 2021, Journal of Clinical Biochemistry and Nutrition — Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
100 healthy older adults, episodic memory and composite cognitive function at 12 weeks.
View StudyKnott V et al. 2015, Journal of Psychopharmacology — Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers
single-dose Cognizin 500 mg / 2000 mg, CPT and P300 ERP modulation.
View StudyDávalos A et al. 2012, Lancet — Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial)
largest stroke RCT, n=2,298, primary endpoint negative, secondary signals modest.
View StudyCotroneo AM et al. 2013, Clinical Interventions in Aging — Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study
VCI study with 9-month follow-up.
View StudyAlvarez-Sabín J et al. 2016, Cerebrovascular Diseases — Citicoline for the prevention of cognitive decline after stroke (CITIMEM)
2-year follow-up post-stroke cognitive function.
View StudyZafonte RD et al. 2012, JAMA — Effect of citicoline on functional and cognitive status among patients with traumatic brain injury (COBRIT)
n=1,213 TBI RCT, primary endpoint negative.
View StudyBrown ES et al. 2015, Journal of Affective Disorders — A randomized, double-blind, placebo-controlled trial of citicoline for cocaine dependence in bipolar I disorder
cocaine craving + bipolar depression adjunctive trial.
View StudyWurtman RJ et al. — Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally
Wurtman's MIT lab, uridine + DHA synaptogenesis triad mechanism.
View StudySecades JJ — Citicoline: Pharmacological and Clinical Review, 2022 update (Revista de Neurologia)
comprehensive 2022 narrative review of citicoline pharmacology and clinical evidence base.
View StudyGareri P et al. 2015, Clinical Interventions in Aging — The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives
narrative pharmacology review.
View StudyFrontiers Neurology 2025 — Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: systematic review and meta-analysis
head-to-head meta showing alpha-GPC superior on SCAG, equivalent on memory.
View StudyGatti G et al. 1992, Eur J Clin Pharmacol — Comparative study of free plasma choline levels following IM administration of L-alpha-glycerylphosphorylcholine and citicoline
original ~25.8 vs 13.1 μmol/L plasma choline comparison.
View StudyExamine.com — Citicoline (CDP-choline) entry
community-facing dose/evidence/safety synthesis.
View StudyCognitive Vitality (ADDF) — Citicoline research review
independent geroscience-focused review.
View StudyCochrane 2020 — Citicoline for treating people with acute ischemic stroke
systematic review of stroke RCTs.
View StudyKyowa Hakko Bio — Cognizin Citicoline product/research portal
Cognizin manufacturer's published trial portfolio.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.